Short Interest in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Decreases By 53.3%

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) saw a large decline in short interest in the month of August. As of August 31st, there was short interest totaling 272,812 shares, a decline of 53.3% from the August 15th total of 584,609 shares. Based on an average daily trading volume, of 1,219,586 shares, the short-interest ratio is currently 0.2 days. Currently, 4.2% of the company’s shares are sold short.

Creative Medical Technology Stock Up 0.8%

Shares of CELZ traded up $0.01 during mid-day trading on Tuesday, hitting $0.89. 118,751 shares of the company’s stock were exchanged, compared to its average volume of 3,509,652. The firm has a market cap of $5.83 million, a price-to-earnings ratio of -0.43 and a beta of 2.04. Creative Medical Technology has a 52 week low of $0.62 and a 52 week high of $6.25. The stock’s 50-day simple moving average is $1.00 and its 200-day simple moving average is $1.68.

Creative Medical Technology (NASDAQ:CELZ) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.02). Analysts forecast that Creative Medical Technology will post -1.18 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on CELZ shares. Wall Street Zen upgraded shares of Creative Medical Technology from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings upgraded shares of Creative Medical Technology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. Finally, Roth Capital restated a “buy” rating on shares of Creative Medical Technology in a research note on Thursday, August 20th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold”.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.